Opportunity Information: Apply for PA 14 215
Apply for PA 14 215
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on May 13, 2014 and posted on May 12, 2014.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Small businesses State governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH Funding Opportunity Announcement PA-14-215, titled "HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R01)," is a discretionary, investigator-initiated research grant opportunity that supports studies aimed at clarifying how commonly used viral vaccine vectors behave in the body and how the host immune system responds to them. The central intent is to build a stronger, more predictive understanding of both the basic biology of natural viral infections and the specific immune and tissue-level interactions triggered by HIV vaccine vectors. This FOA is framed around the idea that vaccine vectors are not just delivery vehicles for HIV antigens; they are biologically active viruses (or virus-derived systems) that can shape immunity in ways that may influence both vaccine performance and safety. By funding mechanistic and translational work in this area, NIH is seeking evidence that can guide the design of safer and more effective HIV vaccine strategies.
A defining feature of the announcement is its focus on four major viral vector families that have been widely used, or seriously considered, as platforms for HIV vaccine development: Adenoviridae, Poxviridae, Herpesviridae, and adeno-associated viruses (AAV). Applications are expected to center on one or more of these vector platforms and examine how they interact with the host in humans or in non-human primates (NHPs), which are frequently used because their immune systems and susceptibility patterns can better approximate key aspects of human immunology in the context of HIV-related research. The scope is intentionally aimed at host-vector interactions, meaning proposals should go beyond simple immunogenicity readouts and dig into the underlying biology: how vectors infect or transduce cells, how innate sensing is triggered, what inflammatory pathways are activated, how vector-specific adaptive responses form and persist, and how those responses reshape the cellular landscape relevant to HIV susceptibility.
A major motivation explicitly highlighted in the FOA is the need for improved safety models that can assess potential vaccine-related effects, including the possibility of increased HIV infection rates under certain conditions. This concern reflects the broader field experience that some vector-induced immune responses may unintentionally expand or activate HIV target cells. The announcement specifically points to immune-activated, vector-specific HIV target cells, such as CD4 T cells, as an example of a mechanism that could theoretically increase susceptibility by increasing the number, activation state, or tissue localization of cells that HIV preferentially infects. In practical terms, the FOA encourages research that can identify when, where, and why these target cells become more abundant or more activated following vector exposure, and how that may vary across vector families, dosing regimens, routes of administration, prior immunity to the vector, or host factors.
Because this is an R01 mechanism, the opportunity is structured to support substantial, hypothesis-driven projects that can produce rigorous, generalizable insights rather than narrowly descriptive observations. The expectation is that funded work will help the field develop better tools, assays, and conceptual models to predict and mitigate risks linked to vector-driven immune activation. That can include building or refining preclinical models in NHPs that more accurately forecast human outcomes, establishing correlates or biomarkers that signal elevated susceptibility risk, and clarifying how vector immunity (pre-existing or vaccine-induced) alters both safety and efficacy. The ultimate practical payoff NIH is aiming for is a clearer path to designing vectors and regimens that preserve strong protective immune responses while avoiding immunologic patterns that could increase HIV acquisition risk.
From an administrative and eligibility standpoint, this opportunity was issued by the National Institutes of Health under the health-related activity categories tied to CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). There is no cost sharing or matching requirement listed, which typically means applicants are not required to provide non-federal matching funds as a condition of the award. Eligibility is broad and includes many types of U.S. organizations such as state and local governments, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), independent school districts, and various tribal governments and organizations. The FOA also explicitly includes a wide range of mission-focused institutions, including HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISISs, among others. Importantly, non-U.S. entities and foreign institutions are eligible, foreign components as defined by NIH policy are allowed, and non-U.S. components of U.S. organizations may also apply, reflecting NIHs interest in globally relevant research and collaborations where scientifically justified.
In terms of timing and lifecycle, the FOA was posted in May 2014 and carried an original and current closing date of January 7, 2017, with an archive date of February 7, 2017. That indicates the solicitation is no longer active for new applications under that specific announcement number, but it remains a useful reference point for the kinds of scientific questions and safety considerations NIH has prioritized in HIV vaccine vector research. For the full archived announcement text and any historical details on requirements, NIH provided an official link through the NIH grants guide (http://grants.nih.gov/grants/guide/pa-files/PA-14-215.html), and the NIH Office of Extramural Research webmaster contact was listed for access or linking issues.
Overall, PA-14-215 is best understood as a targeted call to strengthen the evidence base around how HIV vaccine vectors derived from adenoviruses, poxviruses, herpesviruses, and AAV behave in vivo, how they shape innate and adaptive immunity, and how those effects intersect with HIV susceptibility. The emphasis on developing improved safety models, including mechanisms involving activated CD4 T cells and other HIV target cells, signals a clear priority: reducing uncertainty around vector-related risks while enabling the rational design of vaccine strategies that are both immunologically potent and biologically safe.
FAQs: NIH PA-14-215 (R01) - HIV Vaccine Vector Host Interactions
What is NIH PA-14-215?
PA-14-215 is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) titled "HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R01)." It supported discretionary, investigator-initiated research projects focused on understanding how HIV vaccine vectors behave in the body and how the host immune system responds to them.
What is the main purpose of this FOA?
The FOA aimed to build a stronger, more predictive understanding of (1) the biology of natural viral infections and (2) the immune and tissue-level interactions triggered by HIV vaccine vectors. A core idea is that vaccine vectors are biologically active viruses (or virus-derived systems), not just passive delivery tools for HIV antigens, and their behavior can influence both vaccine performance and safety.
What types of research were encouraged under this announcement?
The announcement emphasized mechanistic and translational studies that go beyond basic immunogenicity measurements and instead clarify how vectors interact with the host. This includes how vectors infect or transduce cells, how innate immune sensing is triggered, what inflammatory pathways are activated, how vector-specific adaptive immunity forms and persists, and how these responses reshape host tissues and cell populations relevant to HIV susceptibility.
Which viral vector families were the focus of PA-14-215?
The FOA was framed around four major viral vector families commonly used or seriously considered for HIV vaccine development: Adenoviridae, Poxviridae, Herpesviridae, and adeno-associated viruses (AAV).
Do applications have to focus on one specific vector family?
Applications were expected to center on one or more of the four highlighted vector families (Adenoviridae, Poxviridae, Herpesviridae, and/or AAV), with the main focus on host-vector interactions for the selected platform(s).
Why does the FOA emphasize host-vector interactions rather than simple immunogenicity outcomes?
The FOA prioritized understanding the underlying biology driving immune outcomes, including innate sensing, inflammatory signaling, vector-specific adaptive responses, and tissue/cellular changes. The goal was to generate insights that are more predictive and generalizable than descriptive readouts alone.
What safety concerns motivated this FOA?
A major motivation was improving safety models for assessing potential vaccine-related effects, including the possibility of increased HIV infection rates under certain conditions. The FOA reflects concerns that some vector-driven immune responses might unintentionally expand or activate HIV target cells, which could theoretically increase susceptibility.
How could a vaccine vector theoretically increase HIV susceptibility, according to the FOA?
The FOA specifically highlighted the concept of immune-activated, vector-specific HIV target cells (such as CD4 T cells). If vector exposure increases the number, activation state, or tissue localization of cells that HIV preferentially infects, susceptibility could theoretically rise under some conditions.
What kinds of factors did the FOA suggest could influence host-vector interactions and risk?
The FOA indicated that host-vector interaction outcomes could vary by vector family, dosing regimen, route of administration, prior immunity to the vector, and host factors. Research was encouraged to identify when, where, and why HIV target cells become more abundant or activated following vector exposure and how those patterns differ across these variables.
What is the funding mechanism for PA-14-215?
This FOA used the NIH R01 mechanism, supporting substantial, hypothesis-driven research projects intended to produce rigorous and broadly useful insights.
What kinds of deliverables or advances was NIH seeking from funded projects?
The FOA emphasized advances that could help the field better predict and mitigate risks linked to vector-driven immune activation. Examples described in the announcement include developing or refining preclinical models (including non-human primate models) that more accurately forecast human outcomes, establishing correlates or biomarkers that signal elevated susceptibility risk, and clarifying how vector immunity (pre-existing or vaccine-induced) affects both safety and efficacy.
Were non-human primate (NHP) studies within scope?
Yes. The FOA explicitly discussed examining host-vector interactions in humans or in non-human primates (NHPs), noting that NHPs are frequently used because their immune systems and susceptibility patterns can better approximate key aspects of human immunology in HIV-related research contexts.
Does the FOA address pre-existing or vaccine-induced immunity to the vector?
Yes. The FOA encouraged research clarifying how vector immunity, whether pre-existing or induced by vaccination, alters both safety and efficacy and may influence immune activation patterns relevant to HIV susceptibility.
Does the opportunity require cost sharing or matching funds?
No cost sharing or matching requirement was listed. This generally means applicants were not required to provide non-federal matching funds as a condition of an award.
Which NIH-related program categories (CFDA) were associated with this FOA?
The FOA was tied to CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Who was eligible to apply?
Eligibility was broad and included many types of U.S. organizations, such as state and local governments, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), independent school districts, and various tribal governments and organizations. The FOA also explicitly referenced mission-focused institutions such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISISs, among others.
Were foreign (non-U.S.) organizations eligible?
Yes. The FOA stated that non-U.S. entities and foreign institutions were eligible, foreign components (as defined by NIH policy) were allowed, and non-U.S. components of U.S. organizations could also apply when scientifically justified.
Is PA-14-215 currently open for applications?
No. The FOA was posted in May 2014 and had an original and current closing date of January 7, 2017, with an archive date of February 7, 2017. That indicates it is no longer active for new applications under that specific announcement number.
Where can someone find the archived FOA text?
The archived announcement was available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-14-215.html.
Who was listed as a contact for access or linking issues?
The NIH Office of Extramural Research webmaster contact was listed for access or linking issues related to the FOA.
What is the overall takeaway of this funding opportunity?
PA-14-215 can be understood as a targeted call to strengthen the evidence base on how HIV vaccine vectors derived from adenoviruses, poxviruses, herpesviruses, and AAV behave in vivo, how they shape innate and adaptive immunity, and how those effects intersect with HIV susceptibility. A prominent theme was developing improved safety models and mechanistic understanding (including mechanisms involving activated CD4 T cells and other HIV target cells) to reduce uncertainty around vector-related risks while enabling safer, more effective HIV vaccine strategies.
Browse more opportunities from the same category: Health
Next opportunity: Water quality monitoring through the National Park Service Vital Signs Program.
Previous opportunity: HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 215
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 215) also looked into and applied for these:
| Funding Opportunity |
|---|
| Renewal Awards of SBIR Phase IIB Grants for Brain and Behavior Tools (R44) Apply for PA 14 219 Funding Number: PA 14 219 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Preventing Injuries and Violence by Informing State Strategies Apply for CDC RFA CE14 1403 Funding Number: CDC RFA CE14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01) Apply for PAR 14 220 Funding Number: PAR 14 220 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Confirmatory Efficacy Clinical Trials of Non Pharmacological Interventions for Mental Disorders (R01) Apply for RFA MH 15 340 Funding Number: RFA MH 15 340 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Local Nongovernmental Partnerships for Sustained Country Leadership in Zimbabwe under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1413 Funding Number: CDC RFA GH14 1413 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| FY14 Partnerships to Increase Coverage in Communities Initiative Apply for MP CPI 14 003 Funding Number: MP CPI 14 003 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Service Area Competition Additional Area (SAC AA) Cincinnati, Ohio Apply for HRSA 14 146 Funding Number: HRSA 14 146 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Limited Competition National Primate Research Centers (P51) Apply for PAR 14 226 Funding Number: PAR 14 226 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multiple Approaches to Increase Awareness and Support among Young Women Diagnosed with Breast Cancer Apply for CDC RFA DP14 1408 Funding Number: CDC RFA DP14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Evidence Based Tele Emergency Network Grant Program Apply for HRSA 14 138 Funding Number: HRSA 14 138 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIH Science Education Partnership Award (SEPA) (R25) Apply for PAR 14 228 Funding Number: PAR 14 228 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Assessment of Elastomeric Respirators in Healthcare Environments (R21) Apply for RFA OH 14 009 Funding Number: RFA OH 14 009 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Expanding Efforts and Strategies to Prevent and Control TB including Multidrug Resistant TB, and TB in vulnerable populations Apply for CDC RFA PS14 1412 Funding Number: CDC RFA PS14 1412 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NEI Center Core Grants for Vision Research (P30) Apply for PAR 14 232 Funding Number: PAR 14 232 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IDeA Networks of Biomedical Research Excellence (INBRE) P20 Apply for PAR 14 233 Funding Number: PAR 14 233 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Economic Modeling for HIV, Viral Hepatitis, Sexually Transmitted Diseases, Tuberculosis and School Health Apply for CDC RFA PS14 1415 Funding Number: CDC RFA PS14 1415 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Advancing Research in Voice Disorders (R21) Apply for PA 14 235 Funding Number: PA 14 235 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Advancing Research in Voice Disorders (R01) Apply for PA 14 236 Funding Number: PA 14 236 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Early Intervention Services Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 15 007 Funding Number: HRSA 15 007 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,300,000 |
| Advancing Community Based Services for Health Activity Apply for SOL 669 13 000056 Funding Number: SOL 669 13 000056 Agency: Agency for International Development Category: Health Funding Amount: $24,800,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 215", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.